A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma
Phase 1
Recruiting
- Conditions
- Relapsed or Refractory Lymphoma Including ENKL
- Interventions
- First Posted Date
- 2025-01-07
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- SymBio Pharmaceuticals
- Target Recruit Count
- 43
- Registration Number
- NCT06761677
- Locations
- 🇯🇵
National Cancer Center Hospital, Chuo-ku, Japan
🇯🇵Cancer Institute Hospital Of JFCR, Koto-ku, Japan
🇯🇵Okayama University Hospital, Okayama, Japan
Study to Confirm of the Safety and Tolerability of Brincidofovir in Subjects With BK Virus Infection (Viremia) After Kidney Transplantation
Phase 2
Terminated
- Conditions
- Kidney TransplantationBK Virus InfectionNephropathy
- Interventions
- First Posted Date
- 2022-08-23
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- SymBio Pharmaceuticals
- Target Recruit Count
- 1
- Registration Number
- NCT05511779
- Locations
- 🇯🇵
Research Site, Tokyo, Japan
A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection
Phase 2
Recruiting
- Conditions
- Adenovirus InfectionsCytomegalovirus Infection
- Interventions
- Drug: BCV
- First Posted Date
- 2021-01-13
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- SymBio Pharmaceuticals
- Target Recruit Count
- 52
- Registration Number
- NCT04706923
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Drug-Drug Interaction Study of Intravenous Administration of SyB V-1901 and Cyclosporine in Japanese Healthy Subjects
- First Posted Date
- 2020-09-09
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- SymBio Pharmaceuticals
- Target Recruit Count
- 13
- Registration Number
- NCT04542252
- Locations
- 🇯🇵
Research Site, Hachioji-shi, Tokyo, Japan
Follow-up Study of SyB L-0501 in Combination With Rituximab to Treat DLBCL
Completed
- Conditions
- Diffuse Large B Cell Lymphoma
- First Posted Date
- 2020-04-21
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- SymBio Pharmaceuticals
- Target Recruit Count
- 25
- Registration Number
- NCT04354402
- Locations
- 🇯🇵
Research Site, Yamagata, Japan
Phase I/II Study of SyB L-0501RI in Combination With Rituximab to Treat Lymphoma
- First Posted Date
- 2019-04-03
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- SymBio Pharmaceuticals
- Target Recruit Count
- 37
- Registration Number
- NCT03900377
- Locations
- 🇯🇵
Research Site, Yamagata, Japan
SyB C-0501(Oral Bendamustine) in Patients With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: SyB C-0501
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- SymBio Pharmaceuticals
- Target Recruit Count
- 18
- Registration Number
- NCT03604679
- Locations
- 🇯🇵
Research Site, Osakasayama, Japan
Study of SyB C-1101 in Patients With Myelodysplastic Syndrome
- First Posted Date
- 2018-04-11
- Last Posted Date
- 2022-11-16
- Lead Sponsor
- SymBio Pharmaceuticals
- Target Recruit Count
- 10
- Registration Number
- NCT03495167
- Locations
- 🇯🇵
Research Site, Kyoto, Japan
Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell Lymphoma
Phase 3
Completed
- Conditions
- Assess the Efficacy and Safety of SyB L-0501 in Combination With Rituximab in Patients With Recurrent or Relapsed DLBCL
- Interventions
- First Posted Date
- 2017-12-14
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- SymBio Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT03372837
- Locations
- 🇯🇵
Research Site, Yamagata, Japan
Study of SyB P-1501 (Fentanyl HCI) for Treatment of Postoperative Pain
- First Posted Date
- 2016-12-30
- Last Posted Date
- 2022-11-17
- Lead Sponsor
- SymBio Pharmaceuticals
- Target Recruit Count
- 49
- Registration Number
- NCT03005899
- Locations
- 🇯🇵
Research Site, Wakayama, Japan
© Copyright 2025. All Rights Reserved by MedPath